INVENTIVA SA - ADR (IVA)       3.78  +0.11 (+3%)

3.78  +0.11 (+3%)

US46124U1079 - ADR

INVENTIVA SA - ADR3.78

NASDAQ:IVA (10/4/2022, 11:53:43 AM)+0.11 (+3%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 09-22 2022-09-22/bmo Earnings (Next) 02-13 2023-02-13
Ins Owners N/A Inst Owners 22.29%
Market Cap 154.50M Shares 40.87M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 87.27
IPO 02-15 2017-02-15

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

IVA Daily chart

Company Profile

Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

Company Info

INVENTIVA SA - ADR

50 rue de Dijon, Daix

Daix OCCITANIE 21121

P: 33380447500.0

CEO: Frederic Cren

Employees: 100

Website: http://inventivapharma.com/

IVA News

News Image3 months ago - Market News VideoOversold Conditions For Inventiva (IVA)News Image4 months ago - Market News VideoInventiva is Now Oversold (IVA)News Image5 months ago - Market News VideoRSI Alert: Inventiva (IVA) Now Oversold

IVA Twits

Here you can normally see the latest stock twits on IVA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example